These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34716911)

  • 41. High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus.
    Gupta A; Anoop S; Ansari IA; Prakash S; Misra A
    Clin Nutr ESPEN; 2021 Dec; 46():519-526. PubMed ID: 34857244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.
    Petta S; Eslam M; Valenti L; Bugianesi E; Barbara M; Cammà C; Porzio M; Rosso C; Fargion S; George J; Craxì A
    Liver Int; 2017 Sep; 37(9):1389-1396. PubMed ID: 28235154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
    J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.
    Milic J; Menozzi V; Schepis F; Malagoli A; Besutti G; Franconi I; Raimondi A; Carli F; Mussini C; Sebastiani G; Guaraldi G
    AIDS; 2020 Nov; 34(13):1915-1921. PubMed ID: 33009010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients.
    Zhang Y; Li J; Ni Y; Wang Y; Liu H
    BMC Endocr Disord; 2021 May; 21(1):100. PubMed ID: 34006273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease.
    Shipovskaya AA; Dudanova OP; Kurbatova IV
    Ter Arkh; 2018 Aug; 90(8):63-68. PubMed ID: 30701940
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD).
    Darmadi D; Ruslie RH
    Rom J Intern Med; 2021 Mar; 59(1):66-72. PubMed ID: 33055315
    [No Abstract]   [Full Text] [Related]  

  • 51. Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years.
    Chen J; Hu P; Wang Y; Zhu Z
    BMC Endocr Disord; 2022 May; 22(1):128. PubMed ID: 35562689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
    Mantovani A; Turino T; Lando MG; Gjini K; Byrne CD; Zusi C; Ravaioli F; Colecchia A; Maffeis C; Salvagno G; Lippi G; Bonora E; Targher G
    Diabetes Metab; 2020 Sep; 46(4):296-303. PubMed ID: 31786361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.
    Mansour A; Mohajeri-Tehrani MR; Samadi M; Gerami H; Qorbani M; Bellissimo N; Poustchi H; Hekmatdoost A
    Acta Diabetol; 2019 Nov; 56(11):1199-1207. PubMed ID: 31197470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease.
    Takeuchi H; Sugimoto K; Oshiro H; Iwatsuka K; Kono S; Yoshimasu Y; Kasai Y; Furuichi Y; Sakamaki K; Itoi T
    J Med Ultrason (2001); 2018 Apr; 45(2):243-249. PubMed ID: 29128938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes.
    Choe EY; Lee YH; Choi YJ; Huh BW; Lee BW; Kim SK; Kang ES; Cha BS; Lee EJ; Huh KB; Younossi ZM
    J Gastroenterol Hepatol; 2018 May; 33(5):1082-1091. PubMed ID: 28990251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
    Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
    Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.